A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195 (English)
- New search for: Eigl, B. J.
- Further information on Eigl, B. J.:
- https://orcid.org/0000-0003-1653-6929
- New search for: North, S.
- New search for: Winquist, E.
- New search for: Finch, D.
- New search for: Wood, L.
- New search for: Sridhar, S. S.
- New search for: Powers, J.
- New search for: Good, J.
- New search for: Sharma, M.
- New search for: Squire, J. A.
- New search for: Bazov, J.
- New search for: Jamaspishvili, T.
- New search for: Cox, M. E.
- New search for: Bradbury, P. A.
- New search for: Eisenhauer, E. A.
- New search for: Chi, K. N.
- New search for: Eigl, B. J.
- Further information on Eigl, B. J.:
- https://orcid.org/0000-0003-1653-6929
- New search for: North, S.
- New search for: Winquist, E.
- New search for: Finch, D.
- New search for: Wood, L.
- New search for: Sridhar, S. S.
- New search for: Powers, J.
- New search for: Good, J.
- New search for: Sharma, M.
- New search for: Squire, J. A.
- New search for: Bazov, J.
- New search for: Jamaspishvili, T.
- New search for: Cox, M. E.
- New search for: Bradbury, P. A.
- New search for: Eisenhauer, E. A.
- New search for: Chi, K. N.
In:
Investigational New Drugs
;
33
, 4
; 969-976
;
2015
-
ISSN:
- Article (Journal) / Electronic Resource
-
Title:A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195
-
Contributors:Eigl, B. J. ( author ) / North, S. ( author ) / Winquist, E. ( author ) / Finch, D. ( author ) / Wood, L. ( author ) / Sridhar, S. S. ( author ) / Powers, J. ( author ) / Good, J. ( author ) / Sharma, M. ( author ) / Squire, J. A. ( author )
-
Published in:Investigational New Drugs ; 33, 4 ; 969-976
-
Publisher:
- New search for: Springer US
- New search for: Springer Science + Business Media B.V
-
Place of publication:Dordrecht [u.a.]
-
Publication date:2015
-
ISSN:
-
ZDBID:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
- New search for: 44.40 / 44.40$jPharmazie$jPharmazeutika
- Further information on Basic classification
-
Keywords:
-
Classification:
BKL: 44.40 Pharmazie, Pharmazeutika / 44.40$jPharmazie$jPharmazeutika -
Source:
Table of contents – Volume 33, Issue 4
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 791
-
Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipidsBujak, Emil / Pretto, Francesca / Neri, Dario et al. | 2015
- 801
-
The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell linesTonissi, Federica / Lattanzio, Laura / Merlano, Marco C. / Infante, Lucia / Lo Nigro, Cristiana / Garrone, Ornella et al. | 2015
- 810
-
Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potencyXie, Xinmei / Wang, Lin / Yang, Wenliang / Yu, Ruishuang / Li, Qingli / Pang, Xiaobin et al. | 2015
- 816
-
In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasisSchott, Sarah / Vallet, Sonia / Tower, Robert J. / Noor, Seema / Tiwari, Sanjay / Schem, Christian / Busch, Christian et al. | 2015
- 827
-
Amidation inhibitors 4-phenyl-3-butenoic acid and 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester are novel HDAC inhibitors with anti-tumorigenic propertiesAli, Amna / Burns, Timothy J. / Lucrezi, Jacob D. / May, Sheldon W. / Green, George R. / Matesic, Diane F. et al. | 2015
- 835
-
Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugsSchreiber-Brynzak, Ekaterina / Klapproth, Erik / Unger, Christine / Lichtscheidl-Schultz, Irene / Göschl, Simone / Schweighofer, Sarah / Trondl, Robert / Dolznig, Helmut / Jakupec, Michael A. / Keppler, Bernhard K. et al. | 2015
- 848
-
Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancerCollery, Philippe / Mohsen, Ahmed / Kermagoret, Anthony / Corre, Samantha / Bastian, Gérard / Tomas, Alain / Wei, Ming / Santoni, François / Guerra, Nadia / Desmaële, Didier et al. | 2015
- 861
-
Cytotoxicity of anthraquinones from the roots of Pentas schimperi towards multi-factorial drug-resistant cancer cellsKuete, Victor / Donfack, Arno R. Nanfack / Mbaveng, Armelle T. / Zeino, Maen / Tane, Pierre / Efferth, Thomas et al. | 2015
- 870
-
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignanciesGarcia-Manero, Guillermo / Tibes, Raoul / Kadia, Tapan / Kantarjian, Hagop / Arellano, Martha / Knight, Emily A. / Xiong, Hao / Qin, Qin / Munasinghe, Wijith / Roberts-Rapp, Lisa et al. | 2015
- 881
-
Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancerHorinouchi, Hidehito / Yamamoto, Noboru / Fujiwara, Yutaka / Sekine, Ikuo / Nokihara, Hiroshi / Kubota, Kaoru / Kanda, Shintaro / Yagishita, Shigehiro / Wakui, Hiroshi / Kitazono, Satoru et al. | 2015
- 890
-
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancerMitri, Zahi / Karakas, Cansu / Wei, Caimiao / Briones, Brian / Simmons, Holly / Ibrahim, Nuhad / Alvarez, Ricardo / Murray, James L. / Keyomarsi, Khandan / Moulder, Stacy et al. | 2015
- 895
-
Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT)Chiu, Joanne W. / Chan, Kelvin / Chen, Eric X. / Siu, Lillian L. / Abdul Razak, Albiruni R. et al. | 2015
- 901
-
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumorsRatain, Mark J. / Geary, David / Undevia, Samir D. / Coronado, Cinthya / Alfaro, Vicente / Iglesias, Jorge L. / Schilsky, Richard L. / Miguel-Lillo, Bernardo et al. | 2015
- 911
-
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liverSaid, Rabih / Kurzrock, Razelle / Naing, Aung / Hong, David S. / Fu, Siqing / Piha-Paul, Sarina A. / Wheler, Jennifer J. / Janku, Filip / Kee, Bryan K. / Bidyasar, Savita et al. | 2015
- 921
-
Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumorsDo, Khanh / Speranza, Giovanna / Chang, Lun-Ching / Polley, Eric C. / Bishop, Rachel / Zhu, Weimin / Trepel, Jane B. / Lee, Sunmin / Lee, Min-Jung / Kinders, Robert J. et al. | 2015
- 931
-
Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinibGiri, Nagdeep / Masters, Joanna C. / Plotka, Anna / Liang, Yali / Boutros, Tanya / Pardo, Patricia / O’Connell, Joseph / Bello, Carlo et al. | 2015
- 942
-
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 doseVenkatakrishnan, Karthik / Kim, Tae Min / Lin, Chia-Chi / Thye, Lim Soon / Chng, Wee Joo / Ma, Brigette / Chen, Ming Huang / Zhou, Xiaofei / Liu, Hua / Kelly, Virginia et al. | 2015
- 954
-
A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 studyNakayama, Norisuke / Sato, Atsushi / Tanaka, Soichi / Shimada, Ken / Konishi, Kazuo / Sasaki, Eisaku / Hibi, Kenji / Ichikawa, Hiroko / Kikuchi, Yoshinori / Sakuyama, Toshikazu et al. | 2015
- 963
-
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium studyPedersen, Katrina S. / Kim, George P. / Foster, Nathan R. / Wang-Gillam, Andrea / Erlichman, Charles / McWilliams, Robert R. et al. | 2015
- 969
-
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195Eigl, B. J. / North, S. / Winquist, E. / Finch, D. / Wood, L. / Sridhar, S. S. / Powers, J. / Good, J. / Sharma, M. / Squire, J. A. et al. | 2015
- 977
-
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancerReddy, S. M. / Kopetz, S. / Morris, J. / Parikh, N. / Qiao, W. / Overman, M. J. / Fogelman, D. / Shureiqi, I. / Jacobs, C. / Malik, Z. et al. | 2015
- 985
-
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)Ma, B. B. Y. / Goh, B. C. / Lim, W. T. / Hui, E. P. / Tan, E. H. / Lopes, G. de Lima / Lo, K. W. / Li, L. / Loong, H. / Foster, N. R. et al. | 2015
- 992
-
Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapyTrendowski, Matthew / Fondy, Thomas P. et al. | 2015